Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases

Ascletis and Alphamab Announce Strategic Collaboration and Licensing Agreement for Anti-PD-L1 to Treat Hepatitis B and Other Viral Diseases

Share this:
January 17, 2019 / Pharma News